Discovering new therapeutic molecules requires more than high-throughput screening alone. Our researchers develop integrated discovery platforms that combine chemistry, biology, automation and computation to identify, evaluate and prioritise molecules with the greatest potential for therapeutic development, enabling faster and more informed decision-making throughout the drug discovery process.

A multidisciplinary approach to development

Diagram showing phage display and non-catalytic residues — Accelerating hit discovery through integrated screening, molecular characterisation and target validation.

Our expertise spans direct-to-biology workflows, high-throughput biochemical screening, high-content phenotypic assays, encoded peptide and macrocycle libraries, covalent ligand discovery, computational hit prioritisation, structural biology, multi-omics, and predictive models of drug absorption and permeability. By integrating these technologies, we rapidly connect molecular activity with biological function while evaluating the properties required for successful therapeutic development.

Together, our complementary platforms bridge molecular discovery and molecular evaluation, enabling researchers to identify promising therapeutic molecules, understand their biological activity and assess their potential for further development. This multidisciplinary approach supports therapeutic innovation across academia, biotechnology and the pharmaceutical industry.